What is the market's earnings forecast for Afya next quarter?

What were the key takeaways from Afya's earnings call?

What is Afya's gross profit margin?

What is Afya's latest dividend and current dividend yield?

What guidance did Afya's management provide for the next earnings period?

What does Afya do and what are its main business segments?

What is the revenue and EPS growth rate for Afya year over year?

What were the key takeaways from Afya’s earnings call?

- **Revenue & Profit Growth**: 13% YoY revenue, 19% YoY EBITDA, 20% YoY net income, driven by medical education expansion. 
- **Strategic Moves**: Acquired FUNIC, repurchased SoftBank shares, and extended debt duration. 
- **Tax Impact**: 2026 effective tax rate expected to rise to 15% due to Pillar Two. 
- **Segment Strengths**: Continuing Ed B2B up 65%, Medical Practice B2P up 11%, ecosystem users reach 304,000. 
- **ESG Leadership**: Delivered 700,000 free consultations, recognized as Brazil's top ESG education company.

**【CEO Summary Section】**
- **Revenue Growth**: 13% year-over-year (YoY) for the 9-month period, driven by medical education expansion and acquisitions (e.g., FUNIC). Adjusted EBITDA rose 19% to BRL 1.292 billion, with a margin of 46.4% (up 200bps YoY). 
- **Operational Highlights**: 25,000+ medical students (6% YoY growth), 3,753 approved medical seats (2% YoY), and 304,000 active ecosystem users. Continuing Education revenue grew 11% YoY, with B2B revenue up 65%. 
- **ESG Initiatives**: Delivered 700,000 free healthcare consultations, exceeding UN SDG targets. Launched Instituto Afya for chronic disease research. 

**【CFO Financial Commentary】**
- **Financial Performance**: Q3 2025 revenue BRL 929 million (+10% YoY), adjusted EBITDA BRL 399 million (+15% YoY). 9-month net income BRL 593 million (+20% YoY), EPS BRL 6.40 (+20% YoY). 
- **Segment Breakdown**: 
  - **Undergraduate**: 14% revenue growth, 86% from medical students. 
  - **Continuing Ed**: 11% revenue growth, B2B up 65%. 
  - **Medical Practice**: 9% revenue growth, B2P up 11%. 
- **Liquidity**: Cash flow from operations BRL 1.292 billion (101.5% cash conversion). Net debt BRL 1.342 billion (0.8x 2025 EBITDA guidance). 

**【Q&A Highlights】**
- **Tax Strategy**: 2025 effective tax rate 9.7% (vs. 5.1% 2024), due to Pillar Two tax provisioning. 2026 rate expected to converge to 15%. 
- **Capital Allocation**: Prioritize M&A (e.g., medical assets), buybacks, and dividends. Repurchased SoftBank shares, extended debt duration to 3.2 years. 
- **Segment Trends**: 
  - **Medical Practice**: Margins up 7pts QoQ due to cost efficiency. iClinic AI adoption accelerating. 
  - **Continuing Ed**: Residency Journey students down 36% due to product bundling, but revenue stable. 
  - **FUNIC Integration**: 60 seats in 1st year, margins to improve as classes mature (2-3 years).

Afya Limited (AFYA) Q3 2025 Earnings Call Transcript

Tuition Fees

Other

Deductions

AFYA

AFYA fundamentals

You can ask Aime